$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

$ytenq Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000112170215000032 Filed on August 13, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2015 Q1
Revenue	$327.0K	$744.0K	$645.0K
YoY Change	-48.26%	6.44%	5.22%
Cost Of Revenue	$347.0K	$90.00K	$84.00K
YoY Change	-55.85%	-78.57%	-49.4%
Gross Profit	-$20.00K	$654.0K	$561.0K
YoY Change	-87.01%	134.41%	25.5%
Gross Profit Margin	-6.12%	87.9%	86.98%
Selling, General & Admin	$1.769M	$2.464M	$2.466M
YoY Change	-28.44%	-7.54%	-21.26%
% of Gross Profit		376.76%	439.57%
Research & Development	$1.660M	-$560.0K	$3.930M
YoY Change	-59.41%	-112.79%	-18.3%
% of Gross Profit		-85.63%	700.53%
Depreciation & Amortization	$70.00K	$40.00K	$55.00K
YoY Change	-30.0%	-71.43%	-71.2%
% of Gross Profit		6.12%	9.8%
Operating Expenses	$1.769M	$2.464M	$2.466M
YoY Change	-28.44%	-7.54%	-21.26%
Operating Profit	-$3.106M	-$6.129M	-$5.830M
YoY Change	-53.7%	-9.36%	-22.17%
Interest Expense	$1.000K	$1.000K	$1.000K
YoY Change	-75.0%	-133.33%	-80.0%
% of Operating Profit
Other Income/Expense, Net	$1.000K	$56.00K	-$13.00K
YoY Change	-83.33%	1300.0%	-316.67%
Pretax Income	-$3.105M	-$380.0K	-$5.840M
YoY Change	-53.73%	-94.38%	-22.03%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$5.848M	-$6.073M	-$5.843M
YoY Change	-25.91%	-16.06%	-28.34%
Net Earnings / Revenue	-1788.38%	-816.26%	-905.89%
Basic Earnings Per Share
Diluted Earnings Per Share	-$83.57M	-$86.71M	-$97.33M
COMMON SHARES
Basic Shares Outstanding	26.98M shares	135.5M shares	135.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.90M	$22.70M	$13.30M
YoY Change	-29.8%	312.73%	27.88%
Cash & Equivalents	$17.89M	$22.71M	$13.26M
Short-Term Investments
Other Short-Term Assets	$1.400M	$1.600M	$800.0K
YoY Change	75.0%	128.57%	-27.27%
Inventory	$375.0K	$600.0K	$555.0K
Prepaid Expenses
Receivables	$276.0K	$600.0K	$139.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.42M	$25.50M	$25.47M
YoY Change	-26.0%	152.48%	59.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$908.0K	$743.0K	$743.0K
YoY Change	81.6%	23.83%	62.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$170.0K	$700.0K	$95.00K
YoY Change	-75.71%	0.0%	0.0%
Total Long-Term Assets	$1.697M	$1.400M	$1.457M
YoY Change	41.42%	7.69%	3.04%
TOTAL ASSETS
Total Short-Term Assets	$20.42M	$25.50M	$25.47M
Total Long-Term Assets	$1.697M	$1.400M	$1.457M
Total Assets	$22.12M	$26.90M	$26.93M
YoY Change	-23.19%	135.96%	54.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$448.0K	$400.0K	$384.0K
YoY Change	12.0%	0.0%	-23.96%
Accrued Expenses	$3.590M	$3.184M	$3.184M
YoY Change	-0.28%	-0.5%	21.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.192M	$3.800M	$3.814M
YoY Change	-0.19%	-13.64%	-2.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$150.0K	$200.0K	$150.0K
YoY Change	-25.0%	0.0%	1.35%
Total Long-Term Liabilities	$150.0K	$200.0K	$150.0K
YoY Change	-25.0%	0.0%	1.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.192M	$3.800M	$3.814M
Total Long-Term Liabilities	$150.0K	$200.0K	$150.0K
Total Liabilities	$4.342M	$4.000M	$3.964M
YoY Change	-1.32%	-11.11%	-2.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$319.8M		-$314.0M
YoY Change			11.86%
Common Stock	$337.7M		$337.0M
YoY Change			96467.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.78M	$23.00M	$22.96M
YoY Change
Total Liabilities & Shareholders Equity	$22.12M	$26.90M	$26.93M
YoY Change	-23.19%	135.96%	54.49%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2015 Q1
OPERATING ACTIVITIES
Net Income	-$5.848M	-$6.073M	-$5.843M
YoY Change	-25.91%	-16.06%	-28.34%
Depreciation, Depletion And Amortization	$70.00K	$40.00K	$55.00K
YoY Change	-30.0%	-71.43%	-71.2%
Cash From Operating Activities	-$4.260M	-$5.470M	-$6.661M
YoY Change	-11.06%	12.09%	-25.7%
INVESTING ACTIVITIES
Capital Expenditures	-$290.0K	-$80.00K	$127.0K
YoY Change	480.0%		27.0%
Acquisitions
YoY Change
Other Investing Activities	$40.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$250.0K	-$80.00K	-$130.0K
YoY Change	400.0%	-101.17%	-102.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-300.0K	15.00M	0.000
YoY Change	-101.2%		-100.0%
NET CHANGE
Cash From Operating Activities	-4.260M	-5.470M	-$6.661M
Cash From Investing Activities	-250.0K	-80.00K	-130.0K
Cash From Financing Activities	-300.0K	15.00M	0.000
Net Change In Cash	-4.810M	9.450M	-$6.661M
YoY Change	-123.97%	389.64%	-25.7%
FREE CASH FLOW
Cash From Operating Activities	-$4.260M	-$5.470M	-$6.661M
Capital Expenditures	-$290.0K	-$80.00K	$127.0K
Free Cash Flow	-$3.970M	-$5.390M	-$6.788M
YoY Change	-16.24%	10.45%	-25.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	mblx	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	270000	USD
	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	259000	USD
	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	218000	USD
CY2015Q2	mblx	Class Of Warrant Or Right Expiration Term ClassOfWarrantOrRightExpirationTerm	P4Y
CY2014Q2	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	4380000	USD
	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	9192000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001121702
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26981214	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	METABOLIX, INC.
CY2014Q4	mblx	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	77000	USD
CY2015Q2	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	4319000	USD
	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	8244000	USD
	mblx	Increase Decrease In Deferred Rent And Long Term Liabilities IncreaseDecreaseInDeferredRentAndLongTermLiabilities	-50000	USD
	mblx	Increase Decrease In Deferred Rent And Long Term Liabilities IncreaseDecreaseInDeferredRentAndLongTermLiabilities	0	USD
CY2014Q2	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	25000	USD
	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	88000	USD
CY2015Q2	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	161000	USD
	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	282000	USD
CY2014Q3	mblx	Number Of Units Purchased NumberOfUnitsPurchased	8333333	shares
	mblx	Period Over Which Capital Resources Are Not Sufficient To Fund Planned Operations PeriodOverWhichCapitalResourcesAreNotSufficientToFundPlannedOperations	P12M
	mblx	Private Placement Issuance Costs Incurred During Noncashor Partial Noncash Transaction PrivatePlacementIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	0	USD
	mblx	Private Placement Issuance Costs Incurred During Noncashor Partial Noncash Transaction PrivatePlacementIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	297000	USD
CY2014Q3	mblx	Unit Price UnitPrice	3.00
CY2015Q2	mblx	Unit Price UnitPrice	0.125
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	333000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	384000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	139000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3709000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3184000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3184000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	564000	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	755000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-64000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-70000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	320707000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	336749000	USD
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1327400	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1342158	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2766191	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1939771	shares
CY2014Q4	us-gaap	Assets Assets	23135000	USD
CY2015Q1	us-gaap	Assets Assets	26925000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	21965000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	25468000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	178000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7698000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5531000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20046000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22707000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22707000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-480000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.98
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22530322	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26959980	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8333333	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22530322	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26959980	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135500000	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22600000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	225000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	270000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7240000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15421000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6074000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11922000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	420000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	586000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	90000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	174000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	7465000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	15575000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	6873000	USD
CY2012	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	38885000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	333000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6762000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-14253000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6073000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	13348000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	147000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	246000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2014Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-473000	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-1136000	USD
CY2015Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	0	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	0	USD
CY2014Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	-0.08
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	-0.20
CY2015Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.00
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.00
CY2014Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	112000	USD
CY2015Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	90000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.24
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.65
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-32000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2621000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1754000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-11916000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.16
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.45
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.26
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.52
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-473000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1136000	USD
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-147000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-165000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-424000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	94000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1741000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-517000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	58000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	99000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-51000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-22000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-28000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	15000000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	13019000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	300000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-31000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	875000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-48000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-74000	USD
CY2014Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2000	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	584000	USD
CY2015Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	546000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	586000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	555000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2000	USD
CY2015Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9000	USD
CY2014Q2	us-gaap	Inventory Write Down InventoryWriteDown	228000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	228000	USD
CY2015Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2015Q2	us-gaap	Investments And Cash InvestmentsAndCash	22707000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	4339000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	3964000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23135000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26925000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4189000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3814000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-2167000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	2661000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	300000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11411000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-209000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13846000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12129000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13366000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12129000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7235000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15389000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6073000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11916000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	56000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	43000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6766000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14263000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6129000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11959000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	447000	USD
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	50000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	756000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	405000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	55000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	450000	USD
CY2014Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	86000	USD
CY2015Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	297000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-30000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-32000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	209000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1508000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1631000	USD
CY2014Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	24914000	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14703000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2014Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	24913000	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14703	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	456000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	743000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	743000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	619000	USD
	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	35000	USD
CY2014Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	624000	USD
CY2015Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	209000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	619000	USD
CY2014Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	420000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-313988000	USD
CY2015Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	346000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2014Q2	us-gaap	Revenue From Grants RevenueFromGrants	463000	USD
CY2015Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1667
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-302072000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	911000	USD
CY2015Q2	us-gaap	Revenue From Grants RevenueFromGrants	470000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	922000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	211000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	313000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	113000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	185000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	699000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1312000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	744000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1389000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2665000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5797000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2464000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4930000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1379000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	894000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	305000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	18796000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	22961000	USD
CY2015Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5831490	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5816379	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23117539	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22838511	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company’s cash equivalents are invested solely in money market funds.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0001121702-15-000032-index-headers.html	Edgar Link	pending
0001121702-15-000032-index.html	Edgar Link	pending
0001121702-15-000032.txt	Edgar Link	pending
0001121702-15-000032-xbrl.zip	Edgar Link	pending
ex-101x2014stock_optionxan.htm	Edgar Link	pending
ex-311x20150630.htm	Edgar Link	pending
ex-312x20150630.htm	Edgar Link	pending
ex-31xamendedandrestatedce.htm	Edgar Link	pending
ex-321x20150630.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mblx-20150630.xml	Edgar Link	completed
mblx-20150630.xsd	Edgar Link	pending
mblx-20150630x10q.htm	Edgar Link	pending
mblx-20150630_cal.xml	Edgar Link	unprocessable
mblx-20150630_def.xml	Edgar Link	unprocessable
mblx-20150630_lab.xml	Edgar Link	unprocessable
mblx-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

2015 Q3 Form 10-Q Financial Statement

#000112170215000032 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ YIELD10 BIOSCIENCE, INC. Stock $ytenq

2015 Q3 Form 10-Q Financial Statement

#000112170215000032 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq